




# PHARMACEUTICAL 2022

Enliven Therapeutics Inc.  
Rank 153 of 466





## PHARMACEUTICAL 2022

Enliven Therapeutics Inc.  
Rank 153 of 466

The relative strengths and weaknesses of Enliven Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enliven Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Enliven Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 113% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	92,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,210
Liabilities, Non-Current	406
Other Assets	700
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	58
Other Revenues	0
Property and Equipment	250
Research and Development	38,442
Selling, General and Administrative Expense	13,000

Output Variable	Value in 1000 USD
Assets	93,646
Liabilities	7,616
Expenses	51,442
Revenues	0
Stockholders Equity	86,030
Net Income	-51,384
Comprehensive Net Income	-51,394
Economic Capital Ratio	191%